Professional article
Open access


Other titleOsteoporosis
Published inRevue médicale suisse, vol. 16, no. 676-677, p. 78-80
Publication date2020-01-15

Except for bisphosphonates, the duration of anti-osteoporotic treatment is not limited to 3 to 5 years. T-score between - 2.0 and - 1.5 DS might be the BMD target to reach before considering discontinuing anti-osteoporosis treatment. A rebound of bone remodeling can occur in some patients despite receiving zoledronate after denosumab discontinuation, and the monitoring of CTX is required. There is no benefit of vitamin D supplementation on musculoskeletal health in the general population, but vitamin D remains indicated in patients with vitamin D deficiency or receiving osteoporosis treatment. A sequential treatment with romosozumab during one year, a bone anabolic anti-sclerostin antibody, followed by two years of denosumab, decreases vertebral and non-vertebral fractures with rapid and substantial BMD gains after 3 years.

  • Bone Density
  • Bone Density Conservation Agents / therapeutic use
  • Bone Remodeling
  • Bone and Bones
  • Denosumab
  • Diphosphonates
  • Humans
  • Osteoporosis / drug therapy
  • Osteoporosis, Postmenopausal / drug therapy
Citation (ISO format)
BIVER, Emmanuel, FERRARI, Serge Livio. Ostéoporose. In: Revue médicale suisse, 2020, vol. 16, n° 676-677, p. 78–80. doi: 10.53738/REVMED.2020.16.676-77.0078
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation08/29/2022 11:52:00 AM
First validation08/29/2022 11:52:00 AM
Update time03/16/2023 10:55:07 AM
Status update03/16/2023 10:55:07 AM
Last indexation01/17/2024 11:15:53 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack